Study of KYN-5356 for cognitive problems in schizophrenia
Part of Mental health clinical trials.
This trial tests an investigational drug, KYN-5356, to see if it can improve thinking and memory problems in adults with schizophrenia. You may join if your schizophrenia is stable and you take only one antipsychotic medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with schizophrenia for at least 1 year.
- Your schizophrenia symptoms have been stable for at least 8 weeks.
- You are between 18 and 55 years old.
- You take only one antipsychotic medication and have been on the same dose for at least 2 months.
- Your body mass index (BMI) is between 18 and 40.
- You do not have a moderate to severe substance use disorder (other than nicotine or caffeine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
This study tests a new combination medication (xanomeline/trospium) to see if it helps improve thinking and memory problems in people with schizophrenia. It lasts about a year, and participants continue their usual antipsychotic treatment.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study tests whether a cognitive training program can help young adults with recent psychosis improve their thinking and memory skills. It involves brain scans and cognitive exercises.
This study tests a new medicine, KR23248, in healthy people to see if it is safe and how the body handles it. It is a first-in-human trial, so the main goal is to find out about side effects and how the drug moves through the body.
This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.
Hear when a new Cognitive Impairment Associated With Schizophrenia (CIAS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.